Dubai, UAE - 9 April, 2019 – CSL Behring, a global biotherapeutics leader, has inaugurated its regional headquarters at Dubai Science Park (DSP), a holistic science-focused business community dedicated to the development of the local healthcare sector. The opening of the new office will strengthen the company’s presence in the Middle East and Africa (MEA) region, ultimately leading to better patient care and increased awareness of treatment options for critical medical conditions.
His Excellency Dr Amin Al Amiri, Assistant Undersecretary, Ministry of Health attended the inauguration along with Markus Staempfli, Vice President and General Manager, CSL Behring, Intercontinental Commercial Operations, Mohammed Haggag, General Manager, CSL Behring MEA and Marwan Abdulaziz Janahi, Managing Director of Dubai Science Park.
Biotherapeutics is one of the fastest-growing segments of the pharmaceutical industry. Its annual growth is estimated at more than 10 percent, compared to conventional pharmaceuticals at seven percent. The UAE’s positive investment climate and its attractiveness as a hub for pharma and healthcare activities has encouraged multiple international companies to set up locally, especially in niche industries.
CSL Behring is a leader in the US$24 billion plasma market. The company’s commitment to innovation is reflected in its development of breakthrough therapies being researched to reduce the risk of early recurrent cardiovascular events, improve the outcomes of organ transplants, and treat sickle cell disease, β-thalassemia and autoimmune diseases.
Marwan Abdulaziz Janahi, Managing Director of Dubai Science Park and Chairing Member of the Pharmaceuticals and Medical Equipment Taskforce of the Dubai Industrial Strategy 2030, said, “As a keen enabler of world-class healthcare – one of the national priorities of the UAE Vision 2021, DSP is proud to host pioneers in the field such as CSL Behring. The inauguration of the company’s regional headquarters aligns with our strategy of attracting internationally recognised pharma and healthcare players. With its collaborative environment and wide range of business offerings, DSP can support CSL Behring in achieving its growth objectives and bringing state-of-the-art treatments to the residents of the GCC region.”
“The opening of our new office in Dubai Science Park demonstrates our growth and the increasing demand for our life-saving products,” said, Markus Staempfli, Vice President and General Manager, CSL Behring, Intercontinental Commercial Operations. “We remain committed to delivering on our promise to patients, and will continue to deepen our footprint in the MEA region to reach more people with medicines that can help to transform their lives.”
With global operational headquarters based in Pennsylvania, USA, CSL Behring owns one of the world’s largest plasma collection networks and operates six research facilities around the world. As part of its growth strategy, the company has placed a strong emphasis on expansion in emerging markets in order to better serve patients’ needs through leveraging the latest technologies to develop and deliver innovative therapies for rare and life-threatening diseases. CSL Behring’s foray into the MEA region is expected to create employment opportunities for local talent.
Currently home to over 350 business partners, Dubai Science Park provides a conducive environment for science companies to set up, grow and flourish. The business community aims to contribute to consolidating Dubai’s position as a preferred destination for local and international companies within the science sector.
About Dubai Science Park
Founded in 2005, Dubai Science Park (DSP) is a vibrant, holistic community dedicated to supporting entrepreneurs, SMEs and MNEs active in the sciences, energy and environmental sectors. With its ample office and laboratory space and robust infrastructure, DSP has created an enabling science-focused ecosystem that is home to more than 350 companies, employing over 3,600 professionals.
Through fostering growth, creativity, research and innovation in the areas of human science, plant science, material science, environmental science and energy science, DSP aims to play a significant role in facilitating a more sustainable and self-sufficient future that maximises the use of indigenous resources and talent.
For more information, please visit www.dsp.ae.
About CSL Behring
CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company’s products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.
CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 22,000 people, and delivers its life-saving therapies to people in more than 60 countries. For inspiring stories about the promise of biotechnology, visit Vita at CSLBehring.com/Vita and follow us on Twitter.com/CSLBehring.
For media inquiries, please contact:
Grace Borsellino
APCO Worldwide
Tel: +971 56 780 2691
Email: gborsellino@apcoworldwide.com
Imaan Jooma
APCO Worldwide
Tel: +971 52 671 0528
Email: ijooma@apcoworldwide.com
Natalie de Vane
CSL Behring
Tel: +1 610 999 8756